Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Orchid Pharma's Q1 FY27 revenue grew 15% YoY to INR304 Cr, with EBITDA more than doubling to INR25 Cr, showing recovery from a tough FY26. Gross margin improved to 33% from 30%. **Operational & Strategic Updates:** The 7-ACA backward integration project is on track for its first commercial batch by March 2027. Cefiderocol commissioning is targeted for December 2026. Exblifep is expanding globally, highlighted by a Russia licensing deal estimated at USD178 million (10-year value) and Europe volumes growing 50% QoQ. **Management Outlook & Investor Angle:** Management noted ongoing competition but anticipates improved regulated market demand in H2. Focus remains on cost discipline, product mix, and realizing merger synergies.

The company is strategically diversifying towards value-based products and new markets, conveying a cautious yet confident long-term sentiment.